The medication, suzetrigine (JOURNAVX (R) ), was FDA-approved in January 2025 and became available at HSS in April 2025. It is the first non-opioid pain reliever released in more than 25 years.
At this year's American Society of Regional Anesthesia and Pain Medicine (ASRA) annual meeting, researchers at Hospital for Special Surgery (HSS) presented two studies focused on glucagon-like peptide ...
At this year’s American Society of Regional Anesthesia and Acute Pain Medicine (ASRA) annual meeting, investigators at ...
DENVER--(BUSINESS WIRE)--Spine surgeons at Hospital for Special Surgery (HSS) reported promising findings for adolescent athletes suffering from pars fracture, a common cause of adolescent back pain ...
NEW YORK--(BUSINESS WIRE)--Hospital for Special Surgery (HSS) has been ranked No. 1 in the nation for orthopedics for a record-breaking 16th consecutive year and No. 3 in the nation for rheumatology ...
New York City-based Hospital for Special Surgery, the nation’s top-ranked orthopedic hospital, is partnering with global growth investor General Atlantic to launch a new, independently operated ...
New York City-based Hospital for Special Surgery, one of the most renowned orthopedic care hospitals worldwide, reported net income of $94.7 million for the first half of the year. Such a profit on ...
Hospital for Special Surgery (HSS), the world's leading academic medical center focused on musculoskeletal health, today announced the appointment of Valarie McPherson, DNP, MBA, NEA-BC, as Vice ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results